NVST
NEUTRAL
$25.94
Live
Envista Holdings Corporation · NYSE
Target $28.69
(+10.6%)
$16.29
52W Range
$30.42
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated May 01, 2026
Market cap
$4.23B
P/E
92.64
ROE
1.6%
Profit margin
1.7%
Debt/Equity
0.51
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
NVST presents a complex profile with a stable Piotroski F-Score of 4/9 and a significant valuation gap, as the current price of $25.94 far exceeds the Graham Number ($10.93) and Intrinsic Value ($8.26). While the company shows strong short-term price momentum (+61.3% 1Y) and a highly attractive Forward P/E of 16.64, its trailing P/E of 92.64 and razor-thin profit margin of 1.73% indicate a precarious transition period. The bullish analyst consensus is countered by bearish insider sentiment and a 0/100 technical trend, suggesting the market is pricing in a recovery that has not yet fully materialized in the fundamentals.
Key Strengths
Strong liquidity with a Current Ratio of 2.38 and Quick Ratio of 1.93
Healthy Gross Margin of 55.02% indicating strong product pricing power
Manageable leverage with a Debt/Equity ratio of 0.51
Consistent revenue growth of 15% YoY
Strong analyst support with a 'Buy' recommendation from 13 analysts
Key Risks
Severe overvaluation relative to defensive metrics (Graham Number $10.93)
Extremely low net profit margin (1.73%) leaving little room for error
Bearish insider activity and technical trends
High trailing P/E (92.64) suggests current price relies heavily on future projections
Poor long-term price performance (-40.3% over 5 years)
AI Fair Value Estimate
Based on comprehensive analysis
$14.6
-43.7% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
37
Weak
20
75
30
60
0
AI Verdict
Speculative Recovery
Key drivers: Forward P/E compression, Revenue growth, Valuation premium vs Intrinsic value
Confidence
85%
Value
20/100
Ref P/E 92.64, Graham Number $10.93
Positives
- Forward P/E is reasonable at 16.64
Watchpoints
- Price is >2x the Graham Number
- Price is >3x the Intrinsic Value
Future
75/100
Ref Growth rates and Forward P/E
Positives
- 15% YoY Revenue growth
- Strong earnings surprise track record (3/4 last quarters)
Watchpoints
- Dependence on massive EPS growth to justify valuation
Past
30/100
Ref Historical price trends
Positives
- Recent 1Y recovery of +61.3%
Watchpoints
- 5Y change of -40.3%
- 3Y change of -32.5%
Health
60/100
Ref Piotroski F-Score 4/9
Positives
- Low Debt/Equity (0.51)
- Strong Current Ratio (2.38)
Watchpoints
- Piotroski F-Score is only 4/9 (Stable, not Strong)
Dividend
0/100
Ref Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$25.94
Analyst Target
$28.69
Upside/Downside
+10.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NVST and closest competitors.
Updated 2026-04-30
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NVST
Envista Holdings Corporation
Primary
|
-40.3% | -32.5% | +61.3% | +28.8% | +2.2% | -4.1% |
|
OPCH
Option Care Health, Inc.
Peer
|
+40.8% | -17.7% | -12.4% | -6.3% | -0.5% | -5.3% |
|
INDV
Indivior Pharmaceuticals, Inc.
Peer
|
+222.2% | +81.2% | +190.6% | +35.3% | +18.7% | +2.3% |
|
AMRX
Amneal Pharmaceuticals, Inc.
Peer
|
+121.9% | +591.9% | +68.0% | +28.7% | +3.5% | +1.7% |
|
LGND
Ligand Pharmaceuticals Incorporated
Peer
|
+126.7% | +173.3% | +102.3% | +15.3% | -7.4% | +2.7% |
NVS
Envista Holdings Corporation
Primary
5Y
-40.3%
3Y
-32.5%
1Y
+61.3%
6M
+28.8%
1M
+2.2%
1W
-4.1%
OPC
Option Care Health, Inc.
Peer
5Y
+40.8%
3Y
-17.7%
1Y
-12.4%
6M
-6.3%
1M
-0.5%
1W
-5.3%
IND
Indivior Pharmaceuticals, Inc.
Peer
5Y
+222.2%
3Y
+81.2%
1Y
+190.6%
6M
+35.3%
1M
+18.7%
1W
+2.3%
AMR
Amneal Pharmaceuticals, Inc.
Peer
5Y
+121.9%
3Y
+591.9%
1Y
+68.0%
6M
+28.7%
1M
+3.5%
1W
+1.7%
LGN
Ligand Pharmaceuticals Incorporated
Peer
5Y
+126.7%
3Y
+173.3%
1Y
+102.3%
6M
+15.3%
1M
-7.4%
1W
+2.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
92.64
Forward P/E
16.64
PEG Ratio
N/A
P/B Ratio
1.37
P/S Ratio
1.55
EV/Revenue
1.71
EV/EBITDA
12.83
Market Cap
$4.23B
Profitability
Profit margins and return metrics
Profit Margin
1.73%
Operating Margin
10.74%
Gross Margin
55.02%
ROE
1.56%
ROA
2.78%
Growth
Revenue and earnings growth rates
Revenue Growth
+15.0%
Earnings Growth
+3146.1%
Q/Q Revenue Growth
+14.96%
Q/Q Earnings Growth
+2641.7%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.51
Moderate
Current Ratio
2.38
Strong
Quick Ratio
1.93
Excellent
Cash/Share
$7.39
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.8B
Gross Margin
54.7%
Op. Margin
12.4%
Net Margin
4.4%
Total Assets
$5.7B
Liabilities
$2.6B
Equity
$3.1B
Debt/Equity
0.83x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
85%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-05
$0.38
+17.6% surprise
2025-10-29
$0.32
+16.0% surprise
2025-07-31
$0.26
+13.5% surprise
Healthcare Sector Comparison
Comparing NVST against 582 companies in the Healthcare sector
(37 bullish, 181 neutral, 364 bearish)
P/E Ratio
92.64
This Stock
vs
71.85
Sector Avg
+28.9%
(Expensive)
Return on Equity (ROE)
1.56%
This Stock
vs
-87.12%
Sector Avg
-101.8%
(Below Avg)
Profit Margin
1.73%
This Stock
vs
-16.02%
Sector Avg
-110.8%
(Weaker)
Debt to Equity
0.51
This Stock
vs
2.6
Sector Avg
-80.3%
(Less Debt)
Revenue Growth
15.0%
This Stock
vs
120.93%
Sector Avg
-87.6%
(Slower)
Current Ratio
2.38
This Stock
vs
4.39
Sector Avg
-45.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NVST
Envista Holdings Corporation
|
NEUTRAL | $4.23B | 92.64 | 1.6% | 1.7% | $25.94 | |
|
OPCH
Option Care Health, Inc.
|
NEUTRAL | $4.2B | 21.16 | 15.2% | 3.7% | $26.87 | Compare |
|
INDV
Indivior Pharmaceuticals, Inc.
|
BULLISH | $4.16B | 20.82 | -% | 16.9% | $34.15 | Compare |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
NEUTRAL | $4.11B | 58.5 | -% | 2.4% | $12.87 | Compare |
|
LGND
Ligand Pharmaceuticals Incorporated
|
NEUTRAL | $4.09B | 33.43 | 13.5% | 46.4% | $204.92 | Compare |
NVST
Envista Holdings...
NEUTRAL
Mkt Cap
$4.2B
P/E
92.6
ROE
1.6%
Price
$25.94
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-25 | HAMMES ERIC D. | Chief Financial Officer | Stock Award | 16,055 | - |
| 2026-02-25 | KEEL PAUL A | Chief Executive Officer | Stock Award | 48,670 | - |
| 2026-02-25 | NANCE MARK E | General Counsel | Stock Award | 12,675 | - |
| 2026-02-25 | REIS MISCHA | Officer | Stock Award | 5,915 | - |
| 2026-02-25 | KAABI FAEZ C | Officer | Stock Award | 13,520 | - |
| 2026-02-25 | BEFIDI ROBERT JR. | Officer | Stock Award | 7,605 | - |
| 2026-02-25 | ACURIO VERONICA | Officer | Stock Award | 7,605 | - |
| 2026-02-25 | NILSSON STEFAN | Officer | Stock Award | 7,605 | - |
| 2026-02-10 | REIS MISCHA | Officer | Sale | 9,675 | $290,250 |
| 2026-02-10 | REIS MISCHA | Officer | Option Exercise | 9,675 | $166,916 |
HAMMES ERIC D.
Chief Financial Officer
2026-02-25
16,055 shares
KEEL PAUL A
Chief Executive Officer
2026-02-25
48,670 shares
NANCE MARK E
General Counsel
2026-02-25
12,675 shares
REIS MISCHA
Officer
2026-02-25
5,915 shares
KAABI FAEZ C
Officer
2026-02-25
13,520 shares
BEFIDI ROBERT JR.
Officer
2026-02-25
7,605 shares
ACURIO VERONICA
Officer
2026-02-25
7,605 shares
NILSSON STEFAN
Officer
2026-02-25
7,605 shares
REIS MISCHA
Officer
2026-02-10
9,675 shares
·
$290,250
REIS MISCHA
Officer
2026-02-10
9,675 shares
·
$166,916
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
10-K
NVST filed its 10-K on February 12, 2026, providing a comprehensive overview of its business operations and financial condition. The filing includes detailed sections on management's discussion and analysis of financial results as well as a dedicated disclosure of the company's risk factors.
8-K
10-Q
8-K
8-K
10-Q
8-K
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
13 analysts
Morgan Stanley
2026-04-24
Equal-Weight
Equal-Weight
Citigroup
2026-04-15
Neutral
Evercore ISI Group
2026-04-08
Outperform
Outperform
Barclays
2026-02-11
Overweight
Overweight
Mizuho
2026-02-10
Neutral
Neutral
JP Morgan
2026-02-06
Neutral
Neutral
Stifel
2026-02-06
Buy
Buy
Wells Fargo
2026-02-06
Equal-Weight
Equal-Weight
Piper Sandler
2026-02-06
Neutral
Neutral
Stifel
2026-02-04
Buy
Buy
Past News Coverage
Recent headlines mentioning NVST from our newsroom.
Newest → oldest
No matching news yet.